Switching off cancer - An overview of G-quadruplex and i-motif functional role in oncogene expression.

DNA can self-assemble into G-quadruplexes and i-motifs non-canonical secondary structures that are formed by guanine-rich sequences and the cytosine-rich sequences, respectively. G-quadruplexes and i-motifs have been closely linked to cancer development since they can regulate genes expression in various promoter regions. Moreover, these structures have gained attention as viable targets for anticancer treatments because of their physicochemical properties and gene-regulatory functions.

The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation.

Pharmacogenetics promises to optimize treatment-related outcomes by informing optimal drug selection and dosing based on an individual's genotype in conjunction with other important clinical factors. Despite significant evidence of genetic associations with drug response, pharmacogenetic testing has not been widely implemented into clinical practice. Among the barriers to broad implementation are limited guidance for how to successfully integrate testing into clinical workflows and limited data on outcomes with pharmacogenetic implementation in clinical practice.

CYP3A5 pharmacogenetic testing for tacrolimus in pediatric heart transplant patients: a budget impact analysis.

Background: Pharmacogenomic testing can optimize drug efficacy and minimize adverse effects. CYP3A5 polymorphisms affect the metabolism of tacrolimus. We sought to estimate the budget impact of preemptive pharmacogenomic testing for CYP3A5 in pediatric heart transplantation patients from an institutional perspective.